Darbepoetin alfa: all 123 studies that test it
Page 1 of 2. Open to participants first (8), then studies with results posted, then the rest; newest registration first within each.
- Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite AthletesEnrolling by invitationNCT07568574Not applicable
- Darbepoetin in Patients Candidates for Liver Transplant. (EPO-LT Trial)RecruitingNCT07169643Phase 3
- National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Single vs Repeated Cycle of Granulocyte Colony-Stimulating Factor (GCSF) & Darbepoetin in Early Decompensated CirrhosisNot yet recruitingNCT07131280Not applicable
- Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis.RecruitingNCT07002827Not applicable
- The Effect of Roxadustat on Renal Oxygenation in Diabetes NephropathyNot yet recruitingNCT05810311Phase 2
- Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm InfantsRecruitingNCT05340465Phase 2
- Darbepoetin in Neonatal Encephalopathy TrialRecruitingNCT04432662Phase 2
- Darbepoetin for Ischemic Neonatal Stroke to Augment RegenerationRecruitingNCT03171818Phase 2
- Mechanisms of EPO-induced HypertensionTerminatedNCT03810911Phase 2Results posted
- The Study of PK, PD, Safety of Multiple Intravenous Injections of BCD-066 and Aranesp in Healthy VolunteersCompletedNCT03693950Phase 1Results posted
- Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm InfantsCompletedNCT03169881Phase 3Results posted
- Mild Encephalopathy in the Newborn Treated With DarbepoetinCompletedNCT03071861Phase 2Results posted
- Cost Comparison Study of Darbepoetin Versus Epoetin Therapy to Treat Anemia in Hemodialysis PatientsCompletedNCT02817555Phase 4Results posted
- Pharmacokinetics and Pharmacodynamics Study of BCD-066 Compared to Aranesp® in Healthy VolunteersCompletedNCT02506881Phase 1Results posted
- Safety and Efficacy Study of BCD-066 Compared to Aranesp® for Anemia Treatment in Chronic Kidney Disease PatientsCompletedNCT02506868Phase 3Results posted
- Darbepoetin Alfa MDS Companion ProtocolCompletedNCT02175277Phase 3Results posted
- Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney DiseaseCompletedNCT01652872Phase 3Results posted
- A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant PatientsCompletedNCT01506947Phase 4Results posted
- Darbe Administration in Newborns Undergoing Cooling for EncephalopathyCompletedNCT01471015Phase 1/2Results posted
- Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)CompletedNCT01362140Phase 3Results posted
- Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)TerminatedNCT01222195Phase 2Results posted
- Darbepoetin Alfa and Anemia of CancerTerminatedNCT00989092Phase 2Results posted
- Evaluation of Monthly Darbepoetin Alfa Dosing for Correction of Anemia in Non-dialysis Chronic Kidney DiseaseCompletedNCT00925587Phase 3Results posted
- Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving ChemotherapyTerminatedNCT00858364Phase 3Results posted
- The Darbepoetin Alfa for Ischemic Surgical Complications (DISC) Dose Finding TrialCompletedNCT00647998Phase 2Results posted
- Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney DiseaseTerminatedNCT00436748Phase 3Results posted
- Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by ChemotherapyCompletedNCT00416624Phase 2Results posted
- STIMULATE Study: Anemia Correction and Health-related Quality of Life (HRQoL) Outcomes in Elderly Chronic Kidney Disease (CKD) PatientsTerminatedNCT00364845Phase 3Results posted
- RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure TrialCompletedNCT00358215Phase 3Results posted
- Darbepoetin Administration to Preterm InfantsCompletedNCT00334737Phase 2Results posted
- Trial to Reduce Cardiovascular Events With Aranesp® Therapy (TREAT)CompletedNCT00093015Phase 3Results posted
- Darbepoetin Alfa Once Monthly Dosing Schedule Maintains Hemoglobin Concentration Comparable to Every 2 Weeks Dosing Schedule in Advanced Chronic Kidney Disease Patients Not on Dialysis: A Multicenter, Phase 4 StudyActive, not recruitingNCT07025460Phase 4
- Comparison of Darbepoetin Alpha and Recombinant Human Erythropoietin for Treatment of Anemia in Children With Chronic Kidney DiseaseCompletedNCT04959578Phase 4
- Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESAActive, not recruitingNCT04798339Phase 1/2
- Desidustat in the Treatment of Anemia in CKDCompletedNCT04012957Phase 3
- A Novel Erythropoiesis Stimulating Protein (NESP; Darbopoetin Alfa) for the Treatment of Anemia in Lung Cancer Patients Receiving Multi-cycle Platinum-Containing ChemotherapyCompletedNCT03776032Phase 3
- CKD-11101 Phase 3 SC StudyCompletedNCT03431623Phase 3
- EPO-4-Rhesus StudyStatus unknownNCT03104426Phase 2/3
- A Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With AnemiaCompletedNCT02952092Phase 3
- Erythropoietin for Management of Anemia Caused by ChemotherapyCompletedNCT02890602Phase 2
- A Study in Healthy Volunteers to Compare the Profiles of DA-3880 and EU Sourced ARANESP® (Amgen)CompletedNCT02241200Phase 1
- PRevention of End Stage Kidney Disease by Darbepoetin Alfa In Chronic Kidney Disease Patients With nondiabeTic Kidney DiseaseCompletedNCT01581073Phase 3
- Intracoronary Darbepoetin-alpha to Reduce The Infarct Size and Post-Infarct RemodelingCompletedNCT01538771Phase 2
- A Clinical Study of KRN321 in Adult Subjects With Myelodysplastic SyndromeCompletedNCT01497145Phase 2
- Study to Evaluate Darbepoetin Alfa in Pediatric Subjects With Anemia Due to Chronic Kidney DiseaseWithdrawnNCT01428154Phase 1
- Effect of Darbepoetin in Contrast-induced NephropathyTerminatedNCT01197235Phase 2/3
- Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic SyndromesCompletedNCT01196715Phase 3
- Intracoronary Injection of Epo After Myocardial Infarct "Intra-CO-EpoMI"CompletedNCT01043991Phase 3
- Prospective, Multicenter, Open Label and Single-arm Study of Darbepoetin Alfa for Anemia in Myelodisplastic Syndrome Patients.TerminatedNCT01039350Phase 2
- A Proof-of-Concept Study of Darbepoetin Alfa in Partial Correction of Anemia in Chinese With Diabetic NephropathyTerminatedNCT00907608Not applicable
- Study of Erythropoietin to Treat Anemia Complicating Chronic Obstructive Pulmonary DiseaseWithdrawnNCT00579046Phase 3
- Study of the Efficacy of Darbepoetin Alfa in the Treatment of Renal AnemiaCompletedNCT00563446Not applicable
- Erythropoietin (Epo) and Venofer Trial After Autologous Hematopoietic Stem Cell Transplantation (HSCT)CompletedNCT00557817Phase 2/3
- Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE)CompletedNCT00544232Phase 3
- Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin AlfaCompletedNCT00540696Phase 2
- Dose-finding Study of Novel Erythropoiesis Stimulating Protein (NESP) for the Treatment of Anaemia in Subjects With Solid Tumours Receiving Multicycle ChemotherapyCompletedNCT00540384Phase 1/2
- An Exploratory Sub-study for the RED-HF™ (Reduction of Events With Darbepoetin Alfa in Heart Failure) TrialTerminatedNCT00534456Phase 3
- Phase 2 Study of Darbepoetin Alfa Extended DosingCompletedNCT00527215Phase 2
- NESP Pediatric StudyCompletedNCT00527137Phase 3
- Fixed Dose NESP Study in Subjects With CRICompletedNCT00526929Phase 2
- Darbepoetin Alpha in Myelodysplastic Syndromes (MDS)Status unknownNCT00443339Phase 2
- Extension From Weekly to Once Every Other Week Darbepoetin Alfa Administration in Subjects With Chronic Kidney Disease Receiving DialysisCompletedNCT00436995Phase 3
- Effect of Darbepoetin Alfa (Aranesp®) on Anemia in Patients With Advanced Hormone Independent Prostate CancerTerminatedNCT00381836Phase 2/3
- Safety of Darbepoetin Alfa Treatment in Patients With Severe Traumatic Brain InjuryCompletedNCT00375869Phase 2
- STAAR-1 Clinical StudyCompletedNCT00369772Phase 4
- STAAR-3 Clinical StudyCompletedNCT00369733Phase 4
- STAAR-2 Clinical StudyCompletedNCT00368901Phase 4
- A Dose Finding Study of KRN321(Darbepoetin Alfa) for the Treatment of Anemia in Subjects With Solid TumorCompletedNCT00359840Phase 2
- Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell TransplantationCompletedNCT00355407Not applicable
- A Double-blind Study of KRN321 for the Treatment of Anemia in Cancer PatientsCompletedNCT00344409Phase 3
- Hematologic Response of Epoetin Alfa (PROCRIT) Versus Darbepoetin Alfa (ARANESP) in Chemotherapy Induced AnemiaCompletedNCT00315484Phase 4
- Combination Chemotherapy With or Without Darbepoetin Alfa in Treating Women With Stage III Breast CancerStatus unknownNCT00309920Not applicable
- Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and IfosfamideCompletedNCT00283621Not applicable
- ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast CancerCompletedNCT00261313Phase 2
- Study of Aranesp to Treat Anemia in Prostate Cancer Patients.CompletedNCT00245895Phase 2
- Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid MalignanciesCompletedNCT00239239Phase 2
- Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS)Status unknownNCT00234143Phase 2/3
- A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS)CompletedNCT00230321Phase 1/2
- Darbepoetin Treatment of Anemia in Children With Chronic Renal FailureCompletedNCT00213291Phase 3
- Evaluation of Iron Supplementation During Darbepoetin Alfa Treatment in Prophylaxis of Severe Anaemia Chemo-InducedTerminatedNCT00210002Phase 2
- Darbepoetin Alfa in Patients With "Poor Prognosis" Germ Cell Tumor Treated With High-Dose Chemotherapy (HD-VIP)CompletedNCT00204633Phase 2
- A Web-based Study of Quality of Life Benefits Associated Aranesp in Anemic Patients With CancerCompletedNCT00153868Phase 4
- Study for the Treatment of Anemia in Patients With Non-myeloid Malignancies Receiving Multicycle Chemotherapy.CompletedNCT00148421Phase 3
- Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast CancerCompletedNCT00146562Phase 2
- R-CHOP-14 Versus R-CHOP-21 and Darbepoetin Alpha in Patients Aged 60-80 Years With Diffuse Large B-cell LymphomaCompletedNCT00144755Phase 3
- Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to ChemotherapyCompletedNCT00144131Phase 2
- AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects With Nonmyeloid MalignanciesCompletedNCT00135317Phase 3
- An Evaluation of Aranesp® in Subjects With Anaemic Chronic Kidney Disease (CKD)CompletedNCT00124098Phase 3
- The Effect of Darbepoetin Upon Rehabilitation for Colorectal Cancer SurgeryCompletedNCT00122720Phase 4
- Efficacy Study: Darbepoetin Alfa for the Treatment of Anemia in Patients With Chronic Kidney DiseaseCompletedNCT00121602Phase 3
- Treatment for Patients With Gynecological Malignancies Who Suffer From Anemia Due to ChemotherapyCompletedNCT00121030Phase 2
- Treatment for Anemic Subjects With Non-Myeloid Malignancies Receiving ChemotherapyCompletedNCT00120705Phase 2
- Treatment for Patients Suffering From Anemia Due to ChemotherapyCompletedNCT00120692Phase 2
- Treatment for Patients With Non-Small Cell Lung Cancer Who Developed Anemia Due to ChemotherapyCompletedNCT00120679Phase 2
- A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin AlfaCompletedNCT00119613Phase 3
- Darbepoetin Alfa Treatment of Anemia in Hemodialysis SubjectsCompletedNCT00119587Phase 3
- A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle ChemotherapyCompletedNCT00118638Phase 3
- A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With a Non-Myeloid MalignancyCompletedNCT00117624Phase 3
- A Study of Repeat-Dose Subcutaneous Darbepoetin Alfa in Subjects With Congestive Heart Failure and Anemia, and a Single Dose in Healthy Age- and Sex-Matched Control SubjectsCompletedNCT00117247Phase 1/2
- Impact of Darbepoetin Alfa on Exercise Tolerance and Left Ventricular Structure in Subjects With Symptomatic Congestive Heart Failure (CHF) and AnemiaCompletedNCT00117234Not applicable